Physician profile
Dean Har
NPI 1104857150
$12,088.86
in general payments reported to CMS, 2019-2025
23 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,054 · 2020: $1,772 · 2021: $1,419 · 2022: $1,300 · 2023: $1,832 · 2024: $2,268 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,543.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,698.96 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,845.46 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,532.61 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,042.51 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $826.65 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Glaxosmithkline, LLC. | $798.15 | 2019-2024 | Arexvy |
| Amgen INC. | $720.68 | 2019-2025 | Repatha, Otezla |
| Amarin Pharma, INC. | $517.25 | 2019-2021 | |
| Abbvie INC. | $474.48 | 2023-2025 | |
| Pfizer INC. | $312.40 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $220.82 | 2019-2020 | |
| Abbott Laboratories | $168.15 | 2022-2024 | Freestyle Libre 3 |
| Ars Pharmaceuticals Operations, INC. | $124.96 | 2025 | Neffy |
| Bayer Healthcare Pharmaceuticals INC. | $124.53 | 2022 | |
| Arbor Pharmaceuticals, INC. | $124.17 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $120.98 | 2024 | |
| Medtronic USA, INC. | $107.73 | 2019 | |
| Mylan Specialty L.P. | $107.21 | 2020-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $86.61 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $67.28 | 2020 | |
| Eisai INC. | $36.78 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $16.72 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Har listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.